Oncoceutics, Inc. and its commercial and academic collaborators will be presenting multiple abstracts at the 2019 annual meeting of the American Association for Cancer Research in Atlanta, Georgia, on March 29th to April 3rd. These abstracts will highlight ONC201’s unique mechanism of action, various single agent and combination data, and characterization of other imipridones, including ONC206.
The list of abstracts, along with the time and location of their presentation, can be found below:
| Abstract
|
Date
|
Location
|
| ONC201
|
||
| 1286 / 1 – ONC201 inhibits RET and IGFBP2 signaling through ATF4 mediated- Integrated stress response in medullary thyroid cancer
|
April 1, 2019, 8:00 AM – 12:00 PM | Section 14 |
| 249 / 12 – Combination of ONC201 with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers
|
March 31, 2019, 1:00 PM – 5:00 PM | Section 10 |
| 5183 / 1 – ONC201 induces acetylation of histone binding within the p21 (CDKN1A) gene promoter
|
April 3, 2019, 8:00 AM – 12:00 PM | Section 35 |
| 2664 / 18 – Differential activation of the integrated stress response correlates with anti-tumor activity of imipridones ONC201 and ONC206 in pediatric sarcomas
|
April 1, 2019, 1:00 PM – 5:00 PM | Section 39 |
| 4808 / 22 – Preclinical studies of the combination of ONC201, radiotherapy and Temozolomide against GBM, DIPG and ATRT cell lines
|
April 3, 2019, 8:00 AM – 12:00 PM | Section 13 |
| 2928 / 16 – New insight into signaling contexts for the administration of the imipridone ONC201 to prostate cancer cells
|
April 2, 2019, 8:00 AM – 12:00 PM | Section 8 |
| 364 / 25 – The dopamine receptor D2 antagonist ONC201 has anti-tumorigenic activity in obesity-driven epithelial ovarian cancer
|
March 31, 2019, 1:00 PM – 5:00 PM | Section 14 |
| 258 / 2 – Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic
|
March 31, 2019, 1:00 PM – 5:00 PM | Section 11 |
| 262 / 6 – Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro
|
March 31, 2019, 1:00 PM – 5:00 PM | Section 11 |
| Neuro-Tumor Club – Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201
|
April 1, 2019, 5:00 PM – 9:00 PM | Emory University School of Medicine James B. Williams Medical Education Building |
| Imipridone GPCR SAR
|
||
| 2749 / 1 – Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules
|
April 2, 2019, 8:00 AM – 12:00 PM | Section 1 |
| ONC206
|
||
| 3877 / 27 – IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology
|
April 2, 2019, 1:00 PM – 5:00 PM | Section 12 |
| Oral Talks
|
||
| 2720 – Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality
|
April 1, 2019, 4:35 PM – 4:50 PM | Room A313 – Georgia World CC |
| Neuro-Tumor Club – IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology
|
April 1, 2019, 8:20 PM – 9:30 PM | Emory University School of Medicine James B. Williams Medical Education Building |
Business Development